Genetic correlates of protection against HIV infection: The ally within

Journal of Internal Medicine

Volumn 265, Issue 1, 2009, Pages 110-124

  Piacentini, L ^a   Biasin, M ^a   Fenizia, C ^a   Clerici, M ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Elite controllers; Exposed uninfected individuals; Exposed seronegative individuals; Genetic correlates; HIV; Long term non progressors

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR5; LEUKOCYTE ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN POLYMORPHISM;

ALLELES; CYTOKINES; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HIV SERONEGATIVITY; HIV-1; HLA ANTIGENS; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, CCR5;

EID: 57449088629     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.02041.x     Document Type: Conference Paper

References (98)

1. Lo Caputo S, Trabattoni D, Vichi F et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 2003 17 : 531 9.
2. Castelletti E, Lo Caputo S, Kuhn L et al. The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection. PLoS ONE 2007 2 : e969.
3. Walker BD. Elite control of HIV Infection: implications for vaccines and treatment. Top HIV Med 2007 15 : 134 6.
4. Birch MR, Learmont JC, Dyer WB et al. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol 2001 22 : 263 70.
5. Goudsmit J, Bogaards JA, Jurriaans S et al. Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia. AIDS 2002 16 : 791 3.
6. Piacentini L, Fenizia C, Naddeo V et al. Not just sheer luck! Immune correlates of protection against HIV-1 infection. Vaccine 2008 26 : 3002 7.
7. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996 382 : 722 5.
8. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996 86 : 367 77.
9. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004 36 : 565 74.
10. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 2004 16 : 1201 10.
11. Rana S, Besson G, Cook DG et al. Role of CCR5 in infection of primary macrophages and lymphocytes by macrophage-tropic strains of human immunodeficiency virus: resistance to patient-derived and prototype isolates resulting from the delta ccr5 mutation. J Virol 1997 71 : 3219 27.
12. Dean M, Carrington M, Winkler C et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996 273 : 1856 62.
13. Meyer L, Magierowska M, Hubert JB et al. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS 1997 11 : F73 8.
14. Wu L, LaRosa G, Kassam N et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997 186 : 1373 81.
15. Smith MW, Dean M, Carrington M et al. CCR5-delta 32 gene deletion in HIV-1 infected patients. Lancet 1997 350 : 741 2.
16. Stewart GJ, Ashton LJ, Biti RA et al. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. AIDS 1997 11 : 1833 8.
17. Cohen OJ, Paolucci S, Bende SM et al. CXCR4 and CCR5 genetic polymorphisms in long-term nonprogressive human immunodeficiency virus infection: lack of association with mutations other than CCR5-Delta32. J Virol 1998 72 : 6215 7.
18. Balotta C, Bagnarelli P, Violin M et al. Homozygous delta 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient. AIDS 1997 11 : F67 71.
19. Theodorou I, Meyer L, Magierowska M et al. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet 1997 349 : 1219 20.
20. O'Brien TR, Winkler C, Dean M et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997 349 : 1219.
21. Biti R, Ffrench R, Young J et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997 3 : 252 3.
22. Heiken H, Becker S, Bastisch I et al. HIV-1 infection in a heterosexual man homozygous for CCR-5 delta32. AIDS 1999 13 : 529 30.
23. Sheppard HW, Celum C, Michael NL et al. HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion. J Acquir Immune Defic Syndr 2002 29 : 307 13.
24. Kuipers H, Workman C, Dyer W et al. An HIV-1-infected individual homozygous for the CCR-5 delta32 allele and the SDF-1 3′A allele. AIDS 1999 13 : 433 4.
25. Martinson JJ, Chapman NH, Rees DC et al. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997 16 : 100 3.
26. Pereyra F, Addo MM, Kaufmann DE et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008 197 : 563 71.
27. Arenzana-Seisdedos F, Parmentier M. Genetics of resistance to HIV infection: role of co-receptors and co-receptor ligands. Semin Immunol 2006 18 : 387 403.
28. Gonzalez E, Bamshad M, Sato N et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A 1999 96 : 12004 9.
29. Mummidi S, Bamshad M, Ahuja SS et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 2000 275 : 18946 61.
30. Jang DH, Choi BS, Kim SS. The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV-infected Koreans. Int J Immunogenet 2008 35 : 101 5.
31. Martin MP, Dean M, Smith MW et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998 282 : 1907 11.
32. McDermott DH, Zimmerman PA, Guignard F et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998 352 : 866 70.
33. Salkowitz JR, Bruse SE, Meyerson H et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro. Clin Immunol 2003 108 : 234 40.
34. Hladik F, Liu H, Speelmon E et al. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission. J Virol 2005 79 : 11677 84.
35. Smith MW, Carrington M, Winkler C et al. CCR2 chemokine receptor and AIDS progression. Nat Med 1997 3 : 1052 3.
36. Anzala AO, Ball TB, Rostron T et al. CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet 1998 351 : 1632 3.
37. Faure S, Meyer L, Costagliola D et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000 287 : 2274 7.
38. Vidal F, Viladés C, Domingo P et al. Chemokines LTNP Study Group. Spanish HIV-1-infected long-term nonprogressors of more than 15 years have an increased frequency of the CX3CR1 249I variant allele. J Acquir Immune Defic Syndr 2005 40 : 527 31.
39. Vasilescu A, Terashima Y, Enomoto M et al. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc Natl Acad Sci U S A 2007 104 : 3354 9.
40. Meddows-Taylor S, Martin DJ, Tiemessen CT. Reduced expression of interleukin-8 receptors A and B on polymorphonuclear neutrophils from persons with human immunodeficiency virus type 1 disease and pulmonary tuberculosis. J Infect Dis 1998 177 : 921 30.
41. Cocchi F, DeVico AL, Garzino-Demo A et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995 270 : 1811 5.
42. Zagury D, Lachgar A, Chams V et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A 1998 95 : 3857 61.
43. Gallo RC, Garzino-Demo A, DeVico AL. HIV infection and pathogenesis: what about chemokines? J Clin Immunol 1999 19 : 293 9.
44. Paxton WA, Liu R, Kang S et al. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998 244 : 66 73.
45. Koning FA, Jansen CA, Dekker J et al. Correlates of resistance to HIV-1 infection in homosexual men with high-risk sexual behaviour. AIDS 2004 18 : 1117 26.
46. Liu H, Chao D, Nakayama EE et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999 96 : 4581 5.
47. Wichukchinda N, Nakayama EE, Rojanawiwat A et al. Protective effects of IL4-589T and RANTES-28G on HIV-1 disease progression in infected Thai females. AIDS 2006 20 : 189 96.
48. McDermott DH, Beecroft MJ, Kleeberger CA et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000 14 : 2671 8.
49. An P, Nelson GW, Wang L et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A 2002 99 : 10002 7.
50. Gonzalez E, Kulkarni H, Bolivar H et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005 307 : 1434 40.
51. Modi WS, Lautenberger J, An P et al. Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression. Am J Hum Genet 2006 79 : 120 8.
52. Modi WS, Goedert JJ, Strathdee S et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003 17 : 2357 65.
53. Winkler C, Modi W, Smith MW et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998 279 : 389 93.
54. Reiche EM, Watanabe MA, Bonametti AM et al. Stromal cell-derived factor 1 (SDF1) genetic polymorphism in a sample of healthy individuals, seronegative individuals exposed to human immunodeficiency virus type 1 (HIV-1) and patients infected with HIV-1 from the Brazilian population. Int J Immunogenet 2006 33 : 127 33.
55. Ioannidis JP, Rosenberg PS, Goedert JJ et al. International meta-analysis of HIV host genetics. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001 135 : 782 95.
56. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003 54 : 535 51.
57. Carrington M, Nelson GW, Martin MP et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999 283 : 1748 52.
58. Tang J, Costello C, Keet IP et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999 15 : 317 24.
59. Klein MR, van der Burg SH, Hovenkamp E et al. Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. J Gen Virol 1998 79 : 2191 201.
60. Goulder PJ, Bunce M, Krausa P et al. Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum Retroviruses 1996 12 : 1691 8.
61. Gillespie GM, Kaul R, Dong T et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. AIDS 2002 16 : 961 72.
62. Goulder PJ, Phillips RE, Colbert RA et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997 3 : 212 7.
63. Kelleher AD, Long C, Holmes EC et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med 2001 193 : 375 86.
64. Flores-Villanueva PO, Yunis EJ, Delgado JC et al. Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 2001 98 : 5140 5.
65. Martin MP, Gao X, Lee JH et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002 31 : 429 34.
66. Lambotte O, Boufassa F, Madec Y et al. SEROCO-HEMOCO Study Group. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005 41 : 1053 6.
67. Migueles SA, Sabbaghian MS, Shupert WL et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000 97 : 2709 14.
68. Lockett SF, Robertson JR, Brettle RP et al. Mismatched human leukocyte antigen alleles protect against heterosexual HIV transmission. J Acquir Immune Defic Syndr 2001 27 : 277 80.
69. Dorak MT, Tang J, Penman-Aguilar A et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004 363 : 2137 9.
70. MacDonald KS, Embree J, Njenga S et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 1998 177 : 551 6.
71. MacDonald KS, Fowke KR, Kimani J et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2000 181 : 1581 9.
72. MacDonald KS, Embree JE, Nagelkerke NJ et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001 183 : 503 6.
73. Chiu YL, Greene WC. The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu Rev Immunol 2008 26 : 317 53.
74. An P, Bleiber G, Duggal P et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004 78 : 11070 6.
75. Valcke HS, Bernard NF, Bruneau J et al. APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 2006 20 : 1984 6.
76. Mariani R, Chen D, Schröfelbauer B et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003 114 : 21 31.
77. Biasin M, Piacentini L, Lo Caputo S et al. Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIV-exposed seronegative individuals. J Infect Dis 2007 195 : 960 4.
78. Jin X, Brooks A, Chen H et al. APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. J Virol 2005 79 : 11513 6.
79. Nisole S, Stoye JP, Saïb A. TRIM family proteins: retroviral restriction and antiviral defence. Nat Rev Microbiol 2005 3 : 799 808.
80. Speelmon EC, Livingston-Rosanoff D, Li SS et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006 80 : 2463 71.
81. Javanbakht H, An P, Gold B et al. Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology 2006 354 : 15 27.
82. van Manen D, Rits MA, Beugeling C et al. The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog 2008 4 : e18.
83. Goldschmidt V, Bleiber G, May M et al. The Swiss HIV Cohort Study. Role of common human TRIM5alpha variants in HIV-1 disease progression. Retrovirology 2006 3 : 54.
84. Ball TB, Ji H, Kimani J et al. Polymorphisms in IRF-1 associated with resistance to HIV-1 infection in highly exposed uninfected Kenyan sex workers. AIDS 2007 21 : 1091 101.
85. Shrestha S, Strathdee SA, Galai N et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006 193 : 16 26.
86. Konenkov VI, Smol'nikova MV. Polymorphism of promotor sites of interleukins-4 and -10 and tumor necrosis factor-alpha genes in HIV-infected patients. Bull Exp Biol Med 2002 133 : 389 91.
87. Biasin M, Boasso A, Piacentini L et al. IL-4 and CXCR4 upregulation in HIV-infected and uninfected individuals from Maharashtra-Mumbai. AIDS 2003 17 : 1563 5.
88. Segat L, Bevilacqua D, Boniotto M et al. IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population. Immunogenetics 2006 58 : 471 3.
89. Diop G, Hirtzig T, Do H et al. Exhaustive genotyping of the interferon alpha receptor 1 (IFNAR1) gene and association of an IFNAR1 protein variant with AIDS progression or susceptibility to HIV-1 infection in a French AIDS cohort. Biomed Pharmacother 2006 60 : 569 77.
90. Do H, Vasilescu A, Diop G et al. Associations of the IL2Ralpha, IL4Ralpha, IL10Ralpha, and IFN (gamma) R1 cytokine receptor genes with AIDS progression in a French AIDS cohort. Immunogenetics 2006 58 : 89 98.
91. Kanari Y, Clerici M, Abe H et al. Genotypes at chromosome 22q12-13 are associated with HIV-1-exposed but uninfected status in Italians. AIDS 2005 19 : 1015 24.
92. Doig D, Chesebro B. Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cellsurface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production. J Exp Med 1979 150 : 10 9.
93. Hasenkrug KJ, Valenzuela A, Letts V et al. Chromosome mapping of Rfv3, a host resistance gene to Friend murine retrovirus. J Virol 1995 69 : 2617 20.
94. Super HJ, Hasenkrug KJ, Simmons S et al. Fine mapping of the Friend retrovirus resistancegene, Rfv3, on mouse chromosome 15. J Virol 1999 73 : 7848 52.
95. Telenti A, Goldstein DB. Genomics meets HIV-1. Nat Rev Microbiol 2006 4 : 865 73.
96. Fellay J, Shianna KV, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007 317 : 944 7.
97. Loeuillet C, Deutsch S, Ciuffi A et al. In vitro whole-genome analysis identifies a susceptibility locus for HIV-1. PLoS Biol 2008 6 : e32.
98. Miyazawa M, Lopalco L, Mazzotta F et al. The "immunologic advantage" of HIV-exposed sieronegative individuals. AIDS 2008 (in press).